Authors
Latest:
Dr. Kuykendall on Toxicity Profiles of Ruxolitinib and Fedratinib in MyelofibrosisAndrew T. Kuykendall, MD, discusses the toxicity profiles of ruxolitinib and fedratinib in myelofibrosis.
Latest:
Dr. Kuykendall on the Potential for Momelotinib in MyelofibrosisAndrew T. Kuykendall, MD, discusses the potential for momelotinib in the treatment of patients with myelofibrosis.
Latest:
Dr. Parsa on the Administration of the G-200 Vaccine in GBMAndrew T. Parsa, MD, PhD, from the University of California, San Francisco, describes the administration of the prophage G-200 for patients with recurrent glioblastoma multiforme.
Latest:
Hypofractionated and Stereotactic Body Radiotherapy in Prostate CancerDespite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.
Latest:
Expert Discusses Improving MRI Testing for Prostate CancerAndrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses improving MRI testing for patients with prostate cancer.
Latest:
Dr. Wei on Trial of Venetoclax Plus Chemotherapy in AMLAndrew Wei, MBBS, PhD, clinical hematologist, head of Leukemia Research Group, Alfred Hospital, discusses venetoclax (Venclexta) plus chemotherapy in advanced myeloid leukemia (AML).
Latest:
Dr. Zhu on Optimal Second-Line Treatment for Patients With HCCAndrew X. Zhu, MD, PhD, professor of Medicine, Harvard Medical School, director of Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the possibility of an optimal second-line treatment for all patients with hepatocellular carcinoma (HCC).
Latest:
Dr. Yee on Treating Patients with Relapsed Disease in Multiple MyelomaAndrew Yee, MD, discusses treating patients with relapsed disease in multiple myeloma.
Latest:
Dr. Zhu on the OS Results of the ClarIDHy Trial in IDH1+ CholangiocarcinomaAndrew Zhu, MD, PhD, discusses the final overall survival results from the phase 3 ClarIDHy trial in previously treated patients with IDH1-mutated cholangiocarcinoma.
Latest:
Dr. Jakubowiak on Initial Efficacy Data From the ATLAS Trial in Multiple MyelomaAndrzej Jakubowiak, MD, PhD, discusses initial efficacy results from the phase 3 ATLAS trial in multiple myeloma.
Latest:
Dr. Hahn on Patients With Prostate Cancer Whom Neither Docetaxel or Abiraterone is an OptionAndy Hahn, MD, a resident at the University of Utah School of Medicine, discusses therapy for patients with prostate cancer whom neither docetaxel or abiraterone acetate (Zytiga) is an option.
Latest:
Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck CancersResearchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.
Latest:
Dr. Chagpar on Novel Agents for Neoadjuvant TNBC TreatmentAnees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses novel agents for neoadjuvant triple-negative breast cancer (TNBC) treatment.
Latest:
Dr. Chagpar on Financial Toxicity and Disparities in Breast CancerAnees Chagpar, MD, MBA, MPH, FACS, FRCS(C), discusses the unmet needs regarding financial toxicities for patients with breast cancer.
Latest:
Dr. Chagpar on Limiting the Spread of COVID-19Anees B. Chagpar, MD, MBA, MPH, FACS, FRCS(C), discusses the importance of taking proactive measures to prevent the spread of the novel 2019 coronavirus.
Latest:
Intraoperative Shave Technique Proves Effective in Breast-Conserving SurgeryData from the SHAVE and SHAVE2 trials, in terms of long-term outcomes vis-à-vis local recurrence, may lend some insight into the impact of adjuvant therapy on reducing the ramifications of a positive margin.
Latest:
Dr. Sanchez on UN Summit for Non-Communicable DiseasesHonduran Oncologist Dr. Angel Sanchez on UN Non-Communicable Diseases Summit
Latest:
Dr. Dispenzieri Discusses Anti-CD38 Monoclonal Antibodies in MyelomaAngela Dispenzieri, MD, a professor of medicine in the division of hematology at the Mayo Clinic, discusses excitement over the development of CD38-targeted monoclonal antibodies as treatments for patients with multiple myeloma.
Latest:
Dr. DeMichele on Importance of Neoadjuvant Care in HER2+ Breast CancerAngela M. DeMichele, MD, professor of Medicine and Epidemiology, University of Pennsylvania, discusses the importance of neoadjuvant treatment for patients with HER2-positive breast cancer.
Latest:
The Longstanding Quest for a Better Endocrine Therapy Continues High-Dose Fulvestrant: Have We Found Its Effective Dose, Combination, Setting, or Sequence?Although several endocrine therapies are available today, the authors of this commentary contend that the quest for a better tamoxifen is ongoing.
Latest:
Dr Secord on the Safety of Mirvetuximab in Recurrent Platinum-Sensitive Ovarian CancerAngeles A. Secord, MD, MHSc, discusses safety findings from the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive ovarian cancer.
Latest:
Early-Stage NSCLC Is Ripe for ChangeFollowing a 2-decade lull in early-stage lung cancer, we are now seeing much better-designed neoadjuvant and adjuvant studies based on proper biomarker selection, as well as optimized treatment choices founded upon recent advances in the metastatic setting.
Latest:
Study Addresses Breast Cancer Monitoring Burden on Metastatic PatientsMelissa K. Accordino, MD, MS, discusses ways to improve the monitoring of patients with metastatic breast cancer.
Latest:
Dr. Fama on GBV-C Infection and Risk of LymphomaAngelo Fama, MD, Division of Hematology, Mayo Clinic, discusses a case control study of the GB Virus-C (GBV-C) infection and the risk of lymphoma.
